North America Advanced Drug Delivery Systems Market Size

North America Advanced Drug Delivery Systems Market Analysis

The North American drug delivery systems market is expected to register a CAGR of around 4.8% during the forecast period.

The COVID-19 pandemic had positively impacted the growth of the advanced drug delivery systems market. Numerous research highlights how advanced drug delivery systems (ADDS) aid in the development of improved therapeutic agent delivery systems (dosage forms). For instance, an article published in Elsevier in November 2021 observed that nanotechnology-based techniques were playing a key role in advancing the diagnosis and production of COVID-19 vaccines. In addition, advanced nanoscience has access to all the necessary tools such as theranostics, nucleic acid testing like reverse transcription polymerase chain reaction (rt-PCR), computed tomography, protein testing, etc., that are essential to incorporate such techniques into feasible strategies. Moreover, with the released restrictions and resumed company activities, the studied market is anticipated to grow over the forecast period.

Factors such as the development of new drugs and biologics, advancements in understanding human biology and diseases, as well as increased R&D spending are expected to boost the market growth over the forecast period.

Advancements in several biology-oriented initiatives have created a unique opportunity to better comprehend the molecular causes of human diseases and generate novel medications and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, which also reduce the rate of drug clearance and avoid drug degradation owing to the environment. Also, advanced drugs and biologics offer increased efficiency with a reduced dosage of pharmaceuticals which require an advanced drug delivery system for the targeted and controlled release of novel molecules in tissues and cells to optimize their potential benefits for patients. For instance, in December 2021, AstraZeneca scientists were working on a wide variety of nanoparticles with the goal of delivering new treatment modalities to previously inaccessible targets and precisely regulating their release in patient-friendly formulations. Thus, such innovation is expected to fuel the market growth.

In addition to medicines and biologics, drug-eluting implants have the potential to offer continuous treatment and lower drug dosages. Advanced sustained-release systems work to treat conditions, including intestinal infections. Self-injecting devices are becoming increasingly popular, and a significant class of medical devices has also lately arisen from the pipeline of biologics, biosimilars, and auto-injectors.

Furthermore, the growing research and development spending by the companies to increase the production of new drugs and biologics is anticipated to fuel market growth. For instance, in September 2022, Novartis invested USD 300 million to increase its production and development capabilities for biological drugs. In addition, the company invested USD 110 million in clinical manufacturing capacity in Slovenia and USD 60 million in development manufacturing capacity in Austria to further integrate biologics development within existing facilities. Also, in September 2022, CuraTeQ Biologics, a wholly-owned subsidiary of Aurobindo Pharma, invested approximately INR 300 crore in the capacity expansion of biologics manufacturing facilities. In addition, the company received approval for entering contract manufacturing operations (CMO) for biologicals.

Moreover, the companies are focusing on adopting various business strategies such as new product launches, partnerships, collaborations, and others which are also contributing to market growth. For instance, in February 2022, NuGen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor Shin-Ya Biotechnology Co. Ltd, for its InsuJet needleless injection system. This is part of a multi-year sales and distribution contract with a minimum commitment of CDN 100,000 during the first two years.

Therefore, owing to the aforementioned factors, such as the increasing advancements in biological drugs, growing R&D spending, and increasing company activities, are anticipated to grow over the forecast period. However, the product recalls of advanced drug delivery and the challenges in nanomedicine-based drug delivery are likely to impede the growth of the advanced drug delivery systems market in North America over the forecast period.